Results 31 to 40 of about 4,421 (195)

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability

Frontiers in Endocrinology, 2018
Background: Cardiovascular disease is a frequent complication of type 1 diabetes (T1D). We evaluated the effectiveness of switching from glargine to degludec in reducing the cardiovascular risk factors, the Framingham risk score (FRS) and visceral ...
Valentina Guarnotta, Giulia Di Bella, Giuseppe Pillitteri, Alessandro Ciresi, Carla Giordano   +4 more
doaj   +1 more source

Switching to Degludec from Other Basal Insulins is Associated with Reduced Hypoglycemia Rates: a Prospective Study [PDF]

, 2019
Observational studies of insulin degludec (degludec) with hypoglycemia events prospectively recorded are ...
Wolden, Michael, Feher, Michael, Koefoed, Mette Marie, Jendle, Johan, de Valk, Harold W, Hansen, Troels Krarup, de Valk, Harold W., Fadini, Gian Paolo, Zimmermann, Esther   +8 more
core   +1 more source

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

BMJ Open Diabetes Research & Care, 2019
Objective With healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value.
Nandu Thalange, Jens Gundgaard, Witesh Parekh, Deniz Tutkunkardas   +3 more
doaj   +1 more source

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

BMC Endocrine Disorders, 2019
Background This analysis evaluates the cost-effectiveness of insulin degludec (degludec) versus biosimilar insulin glargine U100 (glargine U100) in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Bulgaria.
Monika Russel-Szymczyk, Vasil Valov, Alexandra Savova, Manoela Manova   +3 more
doaj   +1 more source

Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes

, 2021
The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra-long effect.
Sellbom, Malin, Malin Sellbom, Charlotta Nilsson, Nilsson, Charlotta   +3 more
core   +1 more source

Modern basal insulins: an ongoing story or the start of a new era?

Сахарный диабет, 2015
Basal insulin represents an essential tool in the treatment of both type 1 and type 2 diabetes mellitus. The development of insulin analogues has improved the possibilities of diabetes treatment.
Ivan Ivanovich Dedov
doaj   +1 more source

Clinical use of insulin degludec

Diabetes Research and Clinical Practice, 2015
The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties ...
Vora, Jiten, Cariou, Bertrand, Evans, Marc, Gross, Jorge Luiz, Harris, Stewart, Landstedt-Hallin, Lena, Mithal, Ambrish, Rodriguez, Martín Rodríguez, Meneghini, Luigi   +8 more
openaire   +2 more sources

Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015

Indian Journal of Endocrinology and Metabolism, 2015
As injectable therapies such as human insulin, insulin analogs, and glucagon-like peptide-1 receptor agonists are used to manage diabetes, correct injection technique is vital for the achievement of glycemic control.
Nikhil Tandon, Sanjay Kalra, Yatan Pal Singh Balhara, Manash P Baruah, Manoj Chadha, Hemraj B Chandalia, Subhankar Chowdhury, Kesavadev Jothydev, Prasanna K. M. Kumar, Madhu S V, Ambrish Mithal, Sonal Modi, Shailesh Pitale, Rakesh Sahay, Rishi Shukla, Annamalai Sundaram, Ambika G Unnikrishnan, Subhash K Wangnoo   +17 more
doaj   +1 more source

Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

Diabetology & Metabolic Syndrome, 2023
Background and aims To assess the cost-effectiveness of utilizing IDegLira in comparison to other treatment regimens ( liraglutide and degludec) in managing type 2 diabetes, taking into account the Chinese healthcare system’s perspective.
Ran Wei, Weihao Wang, Xiusheng Huang, Jingtao Qiao, Jinghe Huang, Chang Xing, Qi Pan, Lixin Guo   +7 more
doaj   +1 more source

Individualisation of basal insulin therapy of type 2 diabetes: evidence from large randomized controlled trials

Сахарный диабет, 2023
Initiation of insulin therapy with basal insulin analogues has become the standard of care for type 2 diabetes mellitus (T2DM). Timely administration of insulin allows not only to slow down the progression of type 2 diabetes, but also to reduce the ...
S. V. Nedogoda, I. N. Barykina, A. S. Salasyuk, V. O. Lutova, E. A. Popova   +4 more
doaj   +1 more source